Single Intravenous Dose of Novel Flurbiprofen-Loaded Proniosome Formulations Provides Prolonged Systemic Exposure and Anti-inflammatory Effect (original) (raw)

Abstract

Vesicular and colloidal delivery systems can be designed to control drug release spatially and temporally to improve drug efficacy and side effect profiles. Niosomes (vesicles prepared from nonionic surfactants in aqueous media) are gaining interest as an alternative vesicular delivery system as they offer advantages such as biocompatibility, chemical stability, low cost, high purity, and versatility. However, the physical stability of niosomes, like other vesicular systems, is limited by vesicle fusion, aggregation, and leakage. Proniosomes (dehydrated powder or gel formulations that spontaneously form niosomes on hydration with aqueous media) can overcome these physical stability problems and are more convenient for sterilization, storage, transport, distribution, and dosing. Proniosomes have mostly been explored for their potential to enhance transdermal and oral absorption. In this study we assess, for the first time, the potential for hydrated proniosomes to sustain systemic ex...

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (52)

  1. Abdelkader, H.; Alani, A. W.; Alany, R. G. Recent advances in non-ionic surfactant vesicles (niosomes): self-assembly, fabrication, characterization, drug delivery applications and limitations. Drug Delivery 2014, 21 (2), 87-100.
  2. Bayindir, Z. S.; Yuksel, N. Provesicles as novel drug delivery systems. Curr. Pharm. Biotechnol. 2015, 16 (4), 344-64.
  3. Radha, G. V.; Rani, T. S.; Sarvani, B. A review on proniosomal drug delivery system for targeted drug action. J. Basic Clin Pharm. 2013, 4 (2), 42-8.
  4. Yasam, V. R.; Jakki, S. L.; Natarajan, J.; Kuppusamy, G. A review on novel vesicular drug delivery: proniosomes. Drug Delivery 2014, 21 (4), 243-9.
  5. Sharma, A.; Sharma, U. S. Liposomes in drug delivery: progress and limitations. Int. J. Pharm. 1997, 154 (2), 123-140.
  6. Azmin, M. N.; Florence, A. T.; Handjani-Vila, R. M.; Stuart, J. F.; Vanlerberghe, G.; Whittaker, J. S. The effect of non-ionic surfactant vesicle (niosome) entrapment on the absorption and distribution of methotrexate in mice. J. Pharm. Pharmacol. 1985, 37 (4), 237-42.
  7. Baillie, A. J.; Florence, A. T.; Hume, L. R.; Muirhead, G. T.; Rogerson, A. The preparation and properties of niosomes-non-ionic surfactant vesicles. J. Pharm. Pharmacol. 1985, 37 (12), 863-8.
  8. Namdeo, A.; Jain, N. K. Niosomal delivery of 5-fluorouracil. J. Microencapsulation 1999, 16 (6), 731-40.
  9. Kuotsu, K.; Mandal, A. S.; Biswas, N.; Guha, A.; Chatterjee, S.; Behera, M.; Kuotsu, K. Niosome: A future of targeted drug delivery systems. J. Adv. Pharm. Technol. Res. 2010, 1 (4), 374-80.
  10. Ahmad, M. Z.; Mohammed, A. A.; Mokhtar Ibrahim, M. Technology overview and drug delivery application of proniosome. Pharm. Dev. Technol. 2016, 1-10.
  11. Blazek-Welsh, A. I.; Rhodes, D. G. Maltodextrin-based proniosomes. AAPS PharmSci 2001, 3 (1), E1.
  12. Blazek-Welsh, A. I.; Rhodes, D. G. SEM imaging predicts quality of niosomes from maltodextrin-based proniosomes. Pharm. Res. 2001, 18 (5), 656-61.
  13. Hu, C.; Rhodes, D. G. Proniosomes: a novel drug carrier preparation. Int. J. Pharm. 2000, 206 (1-2), 109-22.
  14. Sahoo, R. K.; Biswas, N.; Guha, A.; Kuotsu, K. Maltodextrin based proniosomes of nateglinide: bioavailability assessment. Int. J. Biol. Macromol. 2014, 69, 430-4.
  15. Anderson, M.; Omri, A. The effect of different lipid components on the in vitro stability and release kinetics of liposome formulations. Drug Delivery 2004, 11 (1), 33-9.
  16. Manosroi, A.; Jantrawut, P.; Akazawa, H.; Akihisa, T.; Manosroi, W.; Manosroi, J. Transdermal absorption enhancement of gel containing elastic niosomes loaded with gallic acid from Terminalia chebula galls. Pharm. Biol. 2011, 49 (6), 553-62.
  17. Paolino, D.; Cosco, D.; Muzzalupo, R.; Trapasso, E.; Picci, N.; Fresta, M. Innovative bola-surfactant niosomes as topical delivery systems of 5-fluorouracil for the treatment of skin cancer. Int. J. Pharm. 2008, 353 (1-2), 233-42.
  18. Shi, B.; Fang, C.; Pei, Y. Stealth PEG-PHDCA niosomes: effects of chain length of PEG and particle size on niosomes surface properties, in vitro drug release, phagocytic uptake, in vivo pharmacokinetics and antitumor activity. J. Pharm. Sci. 2006, 95 (9), 1873-87.
  19. Cullen, K. Malaria Surveillance-United States, 2011. Center for Disease Control and Prevention. Morbidity and Mortality Weekly Report (MMWR) 2013, 62 (ss05), 1-17.
  20. Kitagawa, H.; Sakai, T.; Saito, H.; Mori, M.; Tazoe, R.; Sugibayashi, T.; Nomura, A. Anti inflammatory and analgesic actions and skin irritation of flurbiprofen by dermal application. Lyakuhin Kenkyu 1993, 13, 869-78.
  21. Kyuki, K.; Tsurumi, K.; Fujimura, H.; Masumoto, S.; Hashimoto, Y. Anti-inflammatory effect of flurbiprofen for dermal application (FP-A). Iyakuhin Kenkyu 1984, 15, 293-98.
  22. Masumoto, S.; Akiba, T.; Okumura, M.; Ichikawa, K.; Hashimoto, Y. Anti-inflammatory effect of flurbiprofen by topical application. Iyakuhin Kenkyu 1982, 13, 878-85.
  23. Li, X.; Qin, F.; Yang, L.; Mo, L.; Li, L.; Hou, L. Sulfatide- containing lipid perfluorooctylbromide nanoparticles as paclitaxel vehicles targeting breast carcinoma. Int. J. Nanomed. 2014, 9, 3971-85.
  24. Berger, N.; Sachse, A.; Bender, J.; Schubert, R.; Brandl, M. Filter extrusion of liposomes using different devices: comparison of liposome size, encapsulation efficiency, and process characteristics. Int. J. Pharm. 2001, 223 (1-2), 55-68.
  25. Gupta, A.; Prajapati, S. K.; Singh, M.; Balamurugan, M. Proniosomal powder of captopril: formulation and evaluation. Mol. Pharmaceutics 2007, 4 (4), 596-9.
  26. Nagarsenker, M. S.; Londhe, V. Y.; Nadkarni, G. D. Preparation and evaluation of liposomal formulations of tropicamide for ocular delivery. Int. J. Pharm. 1999, 190 (1), 63-71.
  27. Manosroi, A.; Chutoprapat, R.; Abe, M.; Manosroi, W.; Manosroi, J. Transdermal absorption enhancement of rice bran bioactive compounds entrapped in niosomes. AAPS PharmSciTech 2012, 13 (1), 323-35.
  28. Kaminskas, L. M.; McLeod, V. M.; Kelly, B. D.; Sberna, G.; Boyd, B. J.; Williamson, M.; Owen, D. J.; Porter, C. J. A comparison of changes to doxorubicin pharmacokinetics, antitumor activity, and toxicity mediated by PEGylated dendrimer and PEGylated liposome drug delivery systems. Nanomedicine 2012, 8 (1), 103-11.
  29. Bock, T. K.; Muller, B. W. A novel assay to determine the hemolytic activity of drugs incorporated in colloidal carrier systems. Pharm. Res. 1994, 11 (4), 589-91.
  30. Trevaskis, N. L.; Hu, L.; Caliph, S. M.; Han, S.; Porter, C. J. The mesenteric lymph duct cannulated rat model: application to the assessment of intestinal lymphatic drug transport. J. Visualized Exp. 2015, No. 97, 45389.
  31. Ludden, T. M.; Beal, S. L.; Sheiner, L. B. Comparison of the Akaike Information Criterion, the Schwarz criterion and the F test as guides to model selection. J. Pharmacokinet. Biopharm. 1994, 22 (5), 431-45.
  32. Cong, H. H.; Khaziakhmetova, V. N.; Zigashina, L. E. Rat paw oedema modeling and NSAIDs: Timing of effects. Int. J. Risk Saf Med. 2015, 27, S76-7.
  33. Posadas, I.; Bucci, M.; Roviezzo, F.; Rossi, A.; Parente, L.; Sautebin, L.; Cirino, G. Carrageenan-induced mouse paw oedema is biphasic, age-weight dependent and displays differential nitric oxide cyclooxygenase-2 expression. Br. J. Pharmacol. 2004, 142 (2), 331-8.
  34. Bhaskar, K.; Anbu, J.; Ravichandiran, V.; Venkateswarlu, V.; Rao, Y. M. Lipid nanoparticles for transdermal delivery of flurbiprofen: formulation, in vitro, ex vivo and in vivo studies. Lipids Health Dis. 2009, 8, 6.
  35. Morris, C. J. Carrageenan-induced paw edema in the rat and mouse. Methods Mol. Biol. 2003, 225, 115-21.
  36. Katare, O. P.; Vyasx, S. P.; Dixit, V. K. Enhanced in vivo performance of liposomal indomethacin derived from effervescent granule based proliposomes. J. Microencapsulation 1995, 12 (5), 487- 93.
  37. Choi, M. J.; Maibach, H. I. Liposomes and niosomes as topical drug delivery systems. Skin Pharmacol Physiol 2005, 18 (5), 209-19.
  38. Rahimpour, Y.; Kouhsoltani, M.; Hamishehkar, H. Proniosomes in transdermal drug delivery. Curr. Pharm. Des. 2015, 21 (20), 2883- 91.
  39. Azeem, A.; Anwer, M. K.; Talegaonkar, S. Niosomes in sustained and targeted drug delivery: some recent advances. J. Drug Target 2009, 17 (9), 671-89.
  40. Winden, E. C. A.; Zuidam, N. J.; Crommelin, D. J. A. Strategies for large scale production and optimized stability of pharmaceutical liposomes developed for parenteral use. In Medical Applications of Liposomes; Lasic, D. D., Papahadjopoulos, D, Eds.; Elsevier: Amsterdam, 1998; pp 567-604.
  41. Hao, Y.; Zhao, F.; Li, N.; Yang, Y.; Li, K. Studies on a high encapsulation of colchicine by a niosome system. Int. J. Pharm. 2002, 244 (1-2), 73-80.
  42. Mokhtar, M.; Sammour, O. A.; Hammad, M. A.; Megrab, N. A. Effect of some formulation parameters on flurbiprofen encapsulation and release rates of niosomes prepared from proniosomes. Int. J. Pharm. 2008, 361 (1-2), 104-11.
  43. Yoshioka, T.; Sternberg, B.; Florence, A. Preparation and properties of vesicles (niosomes) of sorbitan monoesters (Span 20, 40, 60 and 80) and a sorbitan triester (Span 85). Int. J. Pharm. 1994, 105 (1), 1-6.
  44. Wan, L. S. C.; Lee, P. F. S. Studies on surface film of sorbitan esters at the air/water interface. Can. J. Pharm. Sci. 1974, 9, 82-85.
  45. Uchegbu, I.; Florence, A. T. Nonionic Surfactant Vesicles (Niosomes) -Physical and Pharmaceutical Chemistry. Adv. Colloid Interface Sci. 1995, 58 (1), 1-55.
  46. Jamali, F.; Berry, B. W.; Tehrani, M. R.; Russell, A. S. Stereoselective pharmacokinetics of flurbiprofen in humans and rats. J. Pharm. Sci. 1988, 77 (8), 666-9.
  47. Bayindir, Z. S.; Be, A. B.; Yuksel, N. Paclitaxel-loaded niosomes for intravenous administration: pharmacokinetics and tissue distribu- tion in rats. Turk. J. Med. Sci. 2015, 45 (6), 1403-12.
  48. Lv, W.; Guo, J.; Ping, Q.; Song, Y.; Li, J. Comparative pharmacokinetics of breviscapine liposomes in dogs, rabbits and rats. Int. J. Pharm. 2008, 359 (1-2), 118-22.
  49. Beija, M.; Salvayre, R.; Lauth-de Viguerie, N.; Marty, J. D. Colloidal systems for drug delivery: from design to therapy. Trends Biotechnol. 2012, 30 (9), 485-96.
  50. Nehoff, H.; Parayath, N. N.; Domanovitch, L.; Taurin, S.; Greish, K. Nanomedicine for drug targeting: strategies beyond the enhanced permeability and retention effect. Int. J. Nanomed. 2014, 9, 2539-55.
  51. Sercombe, L.; Veerati, T.; Moheimani, F.; Wu, S. Y.; Sood, A. K.; Hua, S. Advances and Challenges of Liposome Assisted Drug Delivery. Front. Pharmacol. 2015, 6, 286.
  52. Chen, M. R.; Dragoo, J. L. The effect of nonsteroidal anti- inflammatory drugs on tissue healing. Knee Surg Sports Traumatol Arthrosc 2013, 21 (3), 540-9.